Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.88, $0.03 worse than the analyst estimate of $0.91. Revenue for the quarter came in at $178.1 million versus the consensus estimate of $173.35 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.